

MSSNY Committee on Addiction and Psychiatric Medicine
Friday, May 10, 2024
8:30AM via zoom

Present

Stephen Hermele, MD Chair
Marvin Rabinowitz, MD Vice-chair
Gregory Pinto, MD Commissioner
Lance Austein, MD
Pratibha Bansal, MD
Richard Blum, MD
Scott Breidbart, MD
Lynda Hohman, MD
Celeste Johns, MD
Brian Johnson, MD
Russell Kamer, MD
Eric King, MD
Amy Rappaport Koreen, MD
Thomas Madejski, MD
Glenn Martin, MD
Neha Pawar, MD
Paul Salzberg, MD
Jeffrey Selzer, MD
Michelle Stern, MD

Excused

Nina Huberman, MD

Absent

Gregory Bunt, MD
Jennifer Cushman, MD
Susan Emerson, MD
Leslie Marino, MD
Hemant Kalia, MD
Inkyu Kang, MD
Mark Silver, MD
Gabrielle Shapiro, MD

Invited Guests

Jerome, Cohen MD MSSNY President
David Jakubowicz, MD MSSNY
President Elect

Staff

Tom Lee, MD MSSNY Executive Vice
President
Pat Clancy, Sr. Vice-
President/Managing Director
Brian M. Land, Administrative Asst.

- 1 **1) Welcome, new committee members**
- 2 **2) Adoption of February 9, 2024 minutes** – Minutes will be adopted with
3 corrections. Item 4 on the February 9 minutes stated the CPH sponsored
4 resolution would require the retirement of licenses. Dr. Jeffrey Selzer
5 corrected that statement to say that there is a resolution related to the
6 option to retire licenses and that he would research what the trajectory was.
7 The purpose of the resolution is to retire the license, without discipline, of a
8 physician who has cognitive impairments.
- 9
- 10 **3) 2024 HOD Resolution 160: MSSNY Opposition to the Legalization of**
11 **Non-prescription Drugs** – Pat Clancy noted that the committee had sunset
12 previous policies dealing with hallucinogens. Ms. Clancy also remarked that
13 the reference committee stated there needed to be more discussion with
14 regards to decriminalization, so it has been referred back to the Council.
15 MSSNY Council has not yet referred it back to the committee but it is
16 expected to be in June. As such, it will be placed on the agenda for the
17 November committee meeting, then to the MSSNY Council for approval. Ms.
18 Clancy also suggested putting together a small subcommittee to formulate a

19 policy. She will send out an email to gauge interest in joining the
20 subcommittee.

21
22 **4) DEA: To reclassify marijuana from Class I to Class III**
23 **Schedule** [https://apnews.com/article/marijuana-biden-dea-](https://apnews.com/article/marijuana-biden-dea-criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8)
24 [criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8](https://apnews.com/article/marijuana-biden-dea-criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8) – Pat
25 Clancy remarked that that MSSNY has traditionally supported moving
26 marijuana from a Schedule 1 drug to a Schedule 3 drug, as well as the AMA.
27 Dr. Russell Kamer noted that marijuana does not meet the criteria for an FDA
28 approved medicine and that there is a difference between medical
29 cannabinoids and marijuana. Dr. Gregory Bunt elaborated further, stating
30 that there has been a recommendation that cannabis be rescheduled to a
31 different category altogether, separate from a legitimate medication. Dr.
32 Richard Blum noted that many other FDA approved drugs come from plants
33 and there is no reason marijuana can't be made as a medicine. He also noted
34 that current research is taking place on THC and that the non-psychoactive
35 portions of the plant would be used medically. Dr. Jeffrey Selzer remarked
36 that the Department of Health is not in charge of the medical aspect of
37 marijuana, that it is the cannabis board that is in charge. Dr. Tom Lee
38 highlighted that medical marijuana has a more defined structure vs.
39 recreation marijuana. Ms. Clancy noted that the AMA has a cannabis
40 taskforce and that she will check with them to see what their process will be
41 regarding the rescheduling of marijuana.

42
43 **5) Adjournment; Next Meeting November 1, 2024**

44